Krystal Biotech
KRYS
234 hedge funds and large institutions have $4.49B invested in Krystal Biotech in 2024 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 62 increasing their positions, 83 reducing their positions, and 25 closing their positions.
164% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 25
48% more capital invested
Capital invested by funds: $3.03B → $4.49B (+$1.46B)
21% more funds holding
Funds holding: 194 → 234 (+40)
2.66% more ownership
Funds ownership: 86.56% → 89.22% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
20% less call options, than puts
Call options by funds: $112M | Put options by funds: $140M
25% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 83
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$258M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.1M |
| 3 |
Goldman Sachs
New York
|
+$28.7M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$14.6M |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$40.7M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$31.2M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$28.7M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$21.3M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$21.2M |
KRYS Hedge Fund Activity: Q1 2024 in Review
234 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q1 2024, worth a combined $4.49B — up 48% from $3.03B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new KRYS positions and 25 closed out — a net gain of 41 holders — while 62 added to existing stakes and 83 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $258M. The largest seller was State Street, cutting an estimated $40.7M.
- 234 institutional investors held Krystal Biotech (KRYS) as of Q1 2024, up from 194 in Q4 2023.
- Funds reported $4.49B of Krystal Biotech stock for Q1 2024, up 48% quarter-over-quarter.
- 66 funds opened new Krystal Biotech positions in Q1 2024 and 25 closed out, a net change of +41 holders.
- The largest Krystal Biotech buyer in Q1 2024 was Fidelity Investments, an estimated $258M added.
- The largest Krystal Biotech seller in Q1 2024 was State Street, an estimated $40.7M sold.
Based on aggregated 13F filings for Q1 2024.